VivoSeq
Other

Craniosynostosis

6

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Craniosynostosis is an early-stage landscape with 6 programs across 3 companies. The most active players are Fresenius Kabi Oncology Ltd., Milestone Pharmaceuticals Inc., Amring. 4 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Fresenius Kabi Oncology Ltd.

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

ApprovedA

Amring

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Enrolling by invitation1 · 25%

Clinical Trials

Trial Activity

The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery
Completed·—·Phase 4·NCT02188576·66 enrolled
Measuring of the Duration of Action of Different Doses of Rocuronium-induced Neuromuscular Block in Infants During Surgical Treatment of Craniosynostosis
Enrolling by invitation·TTamas Vegh, MD·Phase 4·NCT07080528·20 enrolled
Effect of Tranexamic Acid Based on Pharmacokinetics in Pediatric Patients Undergoing Craniosynostosis Surgery: Randomized Controlled Trial
Completed·YYonsei University·N/A·NCT02180321·50 enrolled
Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child
Completed·UUniversity Hospital, Montpellier·N/A·NCT03231085·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)